Header

UZH-Logo

Maintenance Infos

Predictive value of heart rate in treatment of major depression with ketamine in two controlled trials


Meyer, Torsten; Brunovsky, Martin; Horacek, Jiri; Novak, Tomas; Andrashko, Veronika; Seifritz, Erich; Olbrich, Sebastian (2021). Predictive value of heart rate in treatment of major depression with ketamine in two controlled trials. Clinical Neurophysiology, 132(6):1339-1346.

Abstract

Objective: Ketamine has been shown to be effective in treatment of episodes of major depressive disorder (MDD). This controlled study aimed to analyse the predictive and discriminative power of heart rate (HR) and heart rate variability (HRV) for ketamine treatment in MDD.

Methods: In 51 patients, HR and HRV were assessed at baseline before and during ketamine infusion and 24 hours post ketamine infusion. Montgomery-Åsberg Depression Rating Scale (MADRS) was used to assess changes of depressive symptoms. A 30% or 50% reduction of symptoms after 24 hours or within 7 days was defined as response. A linear mixed model was used for analysis.

Results: Ketamine infusion increased HR and HRV power during and after infusion. Responders to ketamine showed a higher HR during the whole course of investigation, including at baseline with medium effect sizes (Cohen's d = 0.47-0.67). Furthermore, HR and HRV power discriminated between responders and non-responders, while normalized low and high frequencies did not.

Conclusion: The findings show a predictive value of HR and HRV power for ketamine treatment. This further underlines the importance of the autonomous nervous system (ANS) and its possible malfunctions in MDD.

Significance: The predictive power of HR and HRV markers should be studied in prospective studies. Neurophysiological markers could improve treatment for MDD via optimizing the choice of treatments.

Abstract

Objective: Ketamine has been shown to be effective in treatment of episodes of major depressive disorder (MDD). This controlled study aimed to analyse the predictive and discriminative power of heart rate (HR) and heart rate variability (HRV) for ketamine treatment in MDD.

Methods: In 51 patients, HR and HRV were assessed at baseline before and during ketamine infusion and 24 hours post ketamine infusion. Montgomery-Åsberg Depression Rating Scale (MADRS) was used to assess changes of depressive symptoms. A 30% or 50% reduction of symptoms after 24 hours or within 7 days was defined as response. A linear mixed model was used for analysis.

Results: Ketamine infusion increased HR and HRV power during and after infusion. Responders to ketamine showed a higher HR during the whole course of investigation, including at baseline with medium effect sizes (Cohen's d = 0.47-0.67). Furthermore, HR and HRV power discriminated between responders and non-responders, while normalized low and high frequencies did not.

Conclusion: The findings show a predictive value of HR and HRV power for ketamine treatment. This further underlines the importance of the autonomous nervous system (ANS) and its possible malfunctions in MDD.

Significance: The predictive power of HR and HRV markers should be studied in prospective studies. Neurophysiological markers could improve treatment for MDD via optimizing the choice of treatments.

Statistics

Citations

Dimensions.ai Metrics
9 citations in Web of Science®
8 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

71 downloads since deposited on 07 Dec 2021
27 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > Psychiatric University Hospital Zurich > Clinic for Psychiatry, Psychotherapy, and Psychosomatics
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Life Sciences > Sensory Systems
Life Sciences > Neurology
Health Sciences > Neurology (clinical)
Health Sciences > Physiology (medical)
Uncontrolled Keywords:Physiology (medical), Clinical Neurology, Neurology, Sensory Systems
Language:English
Date:1 June 2021
Deposited On:07 Dec 2021 07:33
Last Modified:25 Feb 2024 02:50
Publisher:Elsevier
ISSN:1388-2457
OA Status:Hybrid
Free access at:Publisher DOI. An embargo period may apply.
Publisher DOI:https://doi.org/10.1016/j.clinph.2021.01.030
PubMed ID:33888426
Project Information:
  • : FunderCharles University
  • : Grant ID
  • : Project Title
  • Content: Published Version
  • Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)